7.7(top 2%)
impact factor
615(top 50%)
papers
9.3K(top 20%)
citations
43(top 20%)
h-index
7.8(top 2%)
extended IF
621
all documents
10.5K
doc citations
69(top 20%)
g-index

Top Articles

#TitleJournalYearCitations
1CD19: a biomarker for B cell development, lymphoma diagnosis and therapyExperimental Hematology and Oncology2012398
2CD133: a stem cell biomarker and beyondExperimental Hematology and Oncology2013243
3Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysisExperimental Hematology and Oncology2012227
4Complex roles of cAMP–PKA–CREB signaling in cancerExperimental Hematology and Oncology2020202
5CD44 as a tumor biomarker and therapeutic targetExperimental Hematology and Oncology2020177
6Leukemia incidence trends at the global, regional, and national level between 1990 and 2017Experimental Hematology and Oncology2020129
7Mechanisms for estrogen receptor expression in human cancerExperimental Hematology and Oncology2018127
8Breast cancer brain metastases: the last frontierExperimental Hematology and Oncology2015124
9Organoid technology in disease modelling, drug development, personalized treatment and regeneration medicineExperimental Hematology and Oncology2018119
10Risk factors and outcome of COVID-19 in patients with hematological malignanciesExperimental Hematology and Oncology2020119
11The role of neoantigen in immune checkpoint blockade therapyExperimental Hematology and Oncology201899
12Childhood B-acute lymphoblastic leukemia: a genetic updateExperimental Hematology and Oncology201497
13Digitoxin and its analogs as novel cancer therapeuticsExperimental Hematology and Oncology201296
14Diagnostic and therapeutic challenges of EBV-positive mucocutaneous ulcer: a case report and systematic review of the literatureExperimental Hematology and Oncology201586
15Emerging therapies in advanced hepatocellular carcinomaExperimental Hematology and Oncology201885
16The development of bispecific antibodies and their applications in tumor immune escapeExperimental Hematology and Oncology201783
17Advances and perspectives of PARP inhibitorsExperimental Hematology and Oncology201981
18Metaplastic breast cancer: histologic characteristics, prognostic factors and systemic treatment strategiesExperimental Hematology and Oncology201379
19SARS-CoV-2 induced thrombocytopenia as an important biomarker significantly correlated with abnormal coagulation function, increased intravascular blood clot risk and mortality in COVID-19 patientsExperimental Hematology and Oncology202074
20Polo-like kinase 1 as target for cancer therapyExperimental Hematology and Oncology201273
21Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safetyExperimental Hematology and Oncology201271
22Ibrutinib for B cell malignanciesExperimental Hematology and Oncology201468
23Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemiaExperimental Hematology and Oncology201764
24Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatmentExperimental Hematology and Oncology201764
25Engineering better chimeric antigen receptor T cellsExperimental Hematology and Oncology202064
26Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLCExperimental Hematology and Oncology202164
27Research progress on dendritic cell vaccines in cancer immunotherapyExperimental Hematology and Oncology202261
28Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALLExperimental Hematology and Oncology201760
29A global, regional, and national survey on burden and Quality of Care Index (QCI) of hematologic malignancies; global burden of disease systematic analysis 1990–2017Experimental Hematology and Oncology202159
30The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysisExperimental Hematology and Oncology201958
31GATA family transcriptional factors: emerging suspects in hematologic disordersExperimental Hematology and Oncology201557
32Cohesin mutations in myeloid malignancies: underlying mechanismsExperimental Hematology and Oncology201454
33Macrophage, the potential key mediator in CAR-T related CRSExperimental Hematology and Oncology202054
34Gene mutational analysis by NGS and its clinical significance in patients with myelodysplastic syndrome and acute myeloid leukemiaExperimental Hematology and Oncology202054
35YTHDF1 promotes hepatocellular carcinoma progression via activating PI3K/AKT/mTOR signaling pathway and inducing epithelial-mesenchymal transitionExperimental Hematology and Oncology202154
36Targeted and novel therapy in advanced gastric cancerExperimental Hematology and Oncology201953
37Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategiesExperimental Hematology and Oncology202153
38Current management and prognostic features for gastrointestinal stromal tumor (GIST)Experimental Hematology and Oncology201252
39Long noncoding RNAs: pivotal regulators in acute myeloid leukemiaExperimental Hematology and Oncology201552
40Selective inhibitors of nuclear export (SINE) in hematological malignanciesExperimental Hematology and Oncology201552
41Altered expression pattern of miR-29a, miR-29b and the target genes in myeloid leukemiaExperimental Hematology and Oncology201451
42Successful treatment of a Caucasian case of multifocal Castleman’s disease with TAFRO syndrome with a pathophysiology targeted therapy - a case reportExperimental Hematology and Oncology201551
43Increased expression of miR-221 is associated with shorter overall survival in T-cell acute lymphoid leukemiaExperimental Hematology and Oncology201349
44Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicityExperimental Hematology and Oncology201549
45Role of m6A writers, erasers and readers in cancerExperimental Hematology and Oncology202249
46Microenvironment characterization and multi-omics signatures related to prognosis and immunotherapy response of hepatocellular carcinomaExperimental Hematology and Oncology202048
47Clinical implications of recurrent gene mutations in acute myeloid leukemiaExperimental Hematology and Oncology202047
48MiRNA-mediated EMT and CSCs in cancer chemoresistanceExperimental Hematology and Oncology202147
49Thalidomide and its analogues in the treatment of Multiple MyelomaExperimental Hematology and Oncology201245
50Effectiveness of AMD3100 in treatment of leukemia and solid tumors: from original discovery to use in current clinical practiceExperimental Hematology and Oncology201544